The understanding of cancer's genetic basis has revolutionized oncology, paving the way for personalized medicine.  Early research, focusing on identifying single gene mutations like the Philadelphia chromosome in chronic myeloid leukemia (CML), laid the groundwork for targeted therapies such as imatinib. This marked a shift from generalized cytotoxic chemotherapy to therapies specifically targeting oncogenic drivers.  Advances in next-generation sequencing (NGS) have dramatically accelerated this progress, enabling comprehensive genomic profiling of tumor samples.  This allows for the identification of multiple somatic mutations, copy number variations, and gene fusions within individual tumors, revealing the complex interplay of genetic alterations contributing to tumorigenesis.  This wealth of genomic data facilitates the selection of patients most likely to benefit from specific targeted therapies or immunotherapies, maximizing efficacy while minimizing adverse effects.  However, challenges remain, including the identification of optimal biomarker panels for patient stratification, the management of treatment resistance driven by the evolution of further mutations, and the cost-effectiveness of widespread genomic testing.  Nonetheless, the ongoing integration of genomic data into clinical practice promises to further personalize cancer treatment, leading to improved patient outcomes and a more refined understanding of cancer heterogeneity.